Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 44Urinary Bladder Neoplasms 42Testicular Neoplasms 30Carcinoma, Transitional Cell 30Ovarian Neoplasms 28Testicular Germ Cell Tumor 16Carcinoma, Non-Small-Cell Lung 14Melanoma 11Kidney Neoplasms 11Carcinoma, Renal Cell 11Breast Neoplasms 11Wilms Tumor 10Urethral Neoplasms 10Teratoma 10Sarcoma 10Pancreatic Neoplasms 10Central Nervous System Neoplasms 10Colorectal Neoplasms 9Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Stomach Neoplasms 7Ovarian Germ Cell Cancer 7Neoplasms 7Seminoma 6Osteosarcoma 6Neuroblastoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Ureteral Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Urologic Neoplasms × Carboplatin × Genitourinary × Clear all
NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT01599013 2015-12-08

JASINT1

Pierre Fabre Medicament

Phase 2 Completed
69 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

NCT00151034 2015-01-21

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

Phase 2 Completed
33 enrolled
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡